Pablo Fuentes-Cerezuela - Publications

Correction: Characterization of Melanoma of Unknown Primary in the Era of Immunotherapy and Targeted Therapy in Spain: Results from the Prospective Real World Study GEM 1801.

Journal: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico

Published: July 15, 2026

Real-world effectiveness of chemotherapy regimens after immunotherapy in patients with advanced melanoma in Spain: Results from the GEM1801 study.

Journal: Cancer

Published: November 11, 2025

Erratum: BO-112 Plus Pembrolizumab for Patients With Anti-PD-1-Resistant Advanced Melanoma: Phase II Clinical Trial SPOTLIGHT-203.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: July 24, 2025

Title: Characterization of Melanoma of Unknown Primary in the Era of Immunotherapy and Targeted Therapy in Spain: Results from the Prospective Real World Study GEM 1801.

Journal: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico

Published: July 06, 2025

BO-112 Plus Pembrolizumab for Patients With Anti-PD-1-Resistant Advanced Melanoma: Phase II Clinical Trial SPOTLIGHT-203.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: June 27, 2025

Poor efficacy of anti PD-1 antibody based immunotherapy in patients with acral melanoma: results from the Spanish Melanoma Group (GEM) registry.

Journal: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico

Published: June 17, 2025

Treatment outcomes in patients with advanced mucosal melanoma in Spain: results from the real-world GEM1801 study.

Journal: Melanoma research

Published: June 09, 2025

Retreatment and rechallenge with BRAF/MEK inhibitors in patients with metastatic melanoma: results from the real-world Spanish Melanoma Registry (GEM-1801).

Journal: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico

Published: March 26, 2025

Response rate and long-term survival in patients with advanced melanoma: data from the prospective cohort study gem-1801.

Journal: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico

Published: March 12, 2025

An MGRN1-Based Biomarker Combination Accurately Predicts Melanoma Patient Survival.

Journal: International journal of molecular sciences

Published: January 15, 2025

Usefulness of mid-regional pro-adrenomedullin for stratifying risk in emergency department patients with solid tumors attended for febrile neutropenia secondary to chemotherapy.

Journal: Emergencias : revista de la Sociedad Espanola de Medicina de Emergencias

Published: January 14, 2025

Challenges and perspectives in the management of BRAF-mutated metastatic melanoma: Systemic treatment sequencing and brain metastases.

Journal: Cancer treatment reviews

Published: November 06, 2024